PODCAST: President Trump’s Early Trade Policy Moves – What it Means for Business — C&M’s First 100 Days Series
Client Alert | 1 min read | 02.03.17
As part of Crowell & Moring’s “First 100 Days” series, Paul Davies and Andrew Blasi of C&M International, Crowell & Moring’s international policy and regulatory affairs consulting affiliate, discuss the trade policy moves made so far by the Trump Administration, and what it means for businesses who are involved in trade issues. Paul is a director at C&M International and a former Australian trade negotiator. Andrew is an associate director at C&M International and a former staff member of the US-ASEAN Business Council and the U.S. House of Representatives.
Covered in this 16 minute podcast:
- President Trump’s early trade policy emphasis on limiting imports and eliminating the trade deficit.
- Implications of the U.S. withdrawal from TPP and the main takeaways for businesses.
- The president’s upcoming meeting with Prime Minister Abe of Japan and where things stand.
- Thoughts on NAFTA and what businesses might expect.
Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes
Insights
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
The U.S. Government Accountability Office’s (GAO) recent decision in Viderity Inc.—Costs, B-424422.5, Sept. 1, 2026, offers useful insight into what constitutes a legally sufficient conflict of interest investigation. The decision arose in an unusual procedural posture: Viderity initially protested, alleging that an agency evaluator had a personal conflict of interest. After the agency took corrective action, Viderity filed a cost entitlement claim requesting that GAO direct the agency to reimburse Viderity’s protest costs. In evaluating that claim, GAO assessed whether Viderity’s underlying protest ground was “clearly meritorious.”
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
